Xenpozyme is a hydrolytic lysosomal sphingomyelin-specific enzyme replacement therapy designed to replace deficient or defective ASM. The Food and Drug Administration (FDA) has approved Xenpozyme ™ ...
Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency “These significant results for olipudase ...
Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "Acid Sphingomyelinase Deficiency Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Xenpozyme as the first treatment for patients with acid sphingomyelinase deficiency with ...
Please provide your email address to receive an email when new articles are posted on . The Japan Ministry of Health, Labor and Welfare has authorized Xenpozyme for the treatment of adult and ...
(RTTNews) - Sanofi (SNYNF, SNY) said, Olipudase alfa showed positive results in two clinical trials in the treatment of acid sphingomyelinase deficiency in adult and pediatric patients. The randomized ...
SAN FRANCISCO & SCOTTSDALE, Ariz.--(BUSINESS WIRE)--PicnicHealth, the venture-backed startup giving patients unprecedented access to their medical records and the ability to contribute to scientific ...
The U.S. Food and Drug Administration has approved Xenpozyme (olipudase alfa) for pediatric and adult patients with acid sphingomyelinase deficiency (ASMD), a rare genetic disease. ASMD is caused by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results